<DOC>
	<DOCNO>NCT02583906</DOCNO>
	<brief_summary>Evaluation effect CPAP ( continuous positive airway pressure ) treatment PAH ( pulmonary arterial hypertension ) CTEPH ( chronic thromboembolic pulmonary hypertension ) patient suffer sleep disordered breathing .</brief_summary>
	<brief_title>Sleep Disordered Breathing Precapillary Pulmonary Hypertension : Effect CPAP Treatment</brief_title>
	<detailed_description>The primary endpoint study evaluate effect CPAP therapy pulmonary vascular resistance PAH CTEPH patient suffer sleep disordered breathing . The secondary endpoint effect CPAP right atrium right ventricle diameter ejection fraction measure echocardiography , 6 minute walk distance , NYHA class , QOL , endothelial function , sympathetic activity prognosis .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>minimum 18 year old diagnose PAH nonoperable CTEPH operate CTEPH peristent pulmonary hypertension diagnosis PAH base cardiac catherisation diagnosis CTEPH confirm contrastenhanced spiral chest CT , pulmonary angiography V/Q scintigraphy recent diagnosis sleep disorder breathing ( polysomnography realize within 3 month inclusion show AHI 15 ) stable clinical condition least 3 month inclusion define NYHA walk distance difference within 10 % previous 3 month change medical therapy 3 month congenital heart disease moderate severe restrictive obstructive pulmonary disease TLC FEV1 &lt; 60 % predict value BMI 35kg/m2 patient already treat CPAP patient severe sleepiness ( epworth sleepiness scale 18 24/24 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>